Apollo Hospitals delivered largely in-line revenue and a 6%/5% beat on EBITDA/PAT in 1QFY27, driven by improved operating leverage. We maintain BUY with a target price of INR10,160.
Apollo Hospitals and Enterprises delivered largely in-line revenue and better-than-expected EBITDA/PAT in 1QFY27, driven by improved operating leverage, robust patient volumes, and reduced losses from the digital platform. We maintain our BUY rating with a target price of INR10,160.
Ratings and target prices as published by each firm. Each summary condenses that firm's stated view in its own note and is attributed to it; no report text is reproduced.
